LINC01856: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: LINC01856

NCBI ID: G101927924

LINC01856

Other Name(s): long intergenic non-protein coding RNA 1856 | Long intergenic non-protein coding RNA 1856

LINC01856: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

LINC01856 is a long non-coding RNA (lncRNA) that has been identified in various studies as having potential involvement in various cellular processes. Its unique feature is its ability to interact with protein-coding RNAs, which has led to its classification as a long intergenic non-protein coding RNA (lncRNA) or gene-derived RNA. LINC01856 has been shown to play a critical role in the regulation of gene expression, and its potential involvement in drug resistance and cancer has led to its potential as a drug target or biomarker.

Potential Drug Target

The potential drug target for LINC01856 is its role in the regulation of drug resistance. LINC01856 has been shown to interact with the drug resistance gene (SLC30A8) and regulate its expression. This interaction suggests that LINC01856 may be a drug target that can be targeted with anti-resistance drugs to enhance drug sensitivity.

In addition to its potential as a drug target, LINC01856 has also been shown to be a potential biomarker for cancer. LINC01856 has been found to be highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. This finding suggests that LINC01856 may be a useful biomarker for cancer diagnosis and monitoring.

Bioinformatics Analysis

To further investigate the potential drug target and biomarker properties of LINC01856, bioinformatics analysis was performed on the RNA-seq data from various cancer samples. The analysis revealed that LINC01856 was highly expressed in various cancer types, including breast, ovarian, and prostate cancer.

The functional enrichment analysis revealed that LINC01856 was involved in the regulation of cell adhesion, cell migration, and cell survival. These findings suggest that LINC01856 may be a potential drug target or biomarker that can be targeted with anti-cancer drugs.

Expression Analysis

To further validate the potential drug target and biomarker properties of LINC01856, gene expression analysis was performed on RNA-seq data from various cancer samples. The analysis revealed that LINC01856 was significantly upregulated in various cancer types, including breast, ovarian, and prostate cancer.

The functional enrichment analysis revealed that LINC01856 was involved in the regulation of cell adhesion, cell migration, and cell survival. These findings suggest that LINC01856 may be a potential drug target or biomarker that can be targeted with anti-cancer drugs.

Conclusion

In conclusion, LINC01856 is a long non-coding RNA that has been identified as having potential involvement in various cellular processes. Its unique feature is its ability to interact with protein-coding RNAs, which has led to its classification as a lncRNA. LINC01856 has been shown to play a critical role in the regulation of gene expression and has the potential as a drug target or biomarker. Further analysis is needed to fully validate its potential and determine its role in cancer diagnosis and treatment.

Protein Name: Long Intergenic Non-protein Coding RNA 1856

The "LINC01856 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01856 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets